Pluvia Biotech Presents Preclinical Data at SSIEM Annual Symposium
Pluvia Biotech Presents preclinical data of potential PKU treatment PBAS499 at SSIEM Annual Symposium in Porto. This is the first time that PBAS499 data will be shared with the scientific community.
Sarsia portfolio company Pluvia Biotech presents preclinical data showing efficacy, safety and broad applicability for the company’s lead compound PBAS499 at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024. Pluvia has developed small molecule pharmacological chaperones with the potential to stabilize the deficient PAH enzyme, the underlying cause of PKU. Based on extensive efficacy and safety studies, the company carefully selected PBAS499 as its lead compound for future clinical development.